रैंकिंग पर वापस जाएं

Thermo Fisher Scientific Inc (TMO)

Overvalued
HealthcareDiagnostics & ResearchUnited States

Fundamental

61

मूल्य

$660.82

मार्केट कैप

$250.91B

भाग 1 · कंपनी का मूल्य कितना है

अवलोकन

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

बैलेंस शीट और तरलता

राजस्व

$46.34B

पिछले 12 महीने (27/6/2026 तक)

शुद्ध आय

$6.97B

पिछले 12 महीने (27/6/2026 तक)

Free Cash Flow

$6.29B

कुल इक्विटी

$53.41B

कुल देनदारियाँ

$56.93B

Current Ratio

1.55

Interest Coverage

5.46

Debt/EBITDA

3.62

Earnings Per Share

राजस्व और शुद्ध आय

Free Cash Flow

आय विवरण

ऐतिहासिक विवरण

समय के साथ मार्जिन

समय के साथ ऋण

ऋण कितना भारी है

वृद्धि तालिका

वृद्धि — राजस्व

Fair Value अनुमान

सामान्य मामलाअधिक मूल्यांकित

Fair Value

$437.42

वर्तमान मूल्य

$660.82

Margin of Safety

-51.1%

Fair Value सीमा

$284.32 - $590.52

इस्तेमाल किए गए valuation methods के बीच का फैलाव, कोई सांख्यिकीय रूप से calibrated confidence interval नहीं।

अनुमान विधियाँ

विश्लेषकों का लक्ष्य मूल्य:$653.11
डिस्काउंटेड कैश फ्लो (DCF):$291.26
आय गुणक (P/E):$455.96
Graham वृद्धि फॉर्मूला:$207.75
अर्निंग पावर वैल्यू (EPV):$187.20
उचित P/B:$251.52
लाभांश डिस्काउंट (Gordon):$33.18
P/FFO, परिचालन से प्राप्त निधि:इसकी गणना के लिए पर्याप्त डेटा नहीं
मध्य-चक्र आय:$349.15
राजस्व गुणक:$492.07
विश्लेषक सहमति:दृढ़ खरीदें (29B / 7H / 0S)
अंतिम Earnings सरप्राइज़:+4.54%

मूल्यांकन मेट्रिक्स

P/E Ratio

36.31

ROE

12.6%

P/B Ratio

4.74

P/FCF

34.11

Gross Margin

-

ROIC

6.6%

लाभप्रदता Radar

मूल्य सृजन (प्रतिस्पर्धी बढ़त)

ROIC

6.6%

WACC

8.3%

ROIC − WACC

-1.7 pp

ROIC पूंजी की लागत से कम है — कंपनी निवेशित हर डॉलर पर मूल्य नष्ट कर रही है।

Fundamental विश्लेषण मानदंड

पास (19)

  • EPS shows upward trend
  • EPS CAGR 13.95%
  • Price CAGR 15.76%
  • ROIC 6.6%
  • Debt/Equity ratio
  • Operating Margin 17.6%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 13.3%
  • Revenue Growth 5Y 6.7%
  • Analyst Consensus 81% Buy
  • Earnings Surprise avg 3.2%
  • Earnings Quality (OCF/NI) 1.29
  • Share Dilution -1.4%
  • Piotroski F-Score 5/9

फेल (7)

  • P/FCF 34.11
  • P/B Ratio 4.74
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • PEG Ratio 16.99
  • Net Margin Trend 15.0% vs 15.2%

अनुपलब्ध (2)

  • Gross Margin NaN%
  • Dividend Payout NaN%

Piotroski F-Score

5/9

मिश्रित संकेत: कुछ क्षेत्रों पर ध्यान देना आवश्यक

score
criteria

Earnings गुणवत्ता

1.29

उच्च गुणवत्ता: earnings नकदी द्वारा समर्थित

शेयर Dilution

-1.4%

शेयर वापस खरीद रही है। शेयरधारक अनुकूल

संस्थागत होल्डिंग

प्रशासन

कार्यकारी टीम

नामपदआयु
Mr. Marc N. CasperChairman & CEO57
Mr. Gianluca PettitiPresident, COO & President of Products and Technologies46
Mr. James R. MeyerSenior VP & CFO45
Mr. Joseph R. HolmesVP & Chief Accounting Officer45
Mr. Ryan J. SnyderSenior VP & Chief Information Officer-
Dr. Karen E. Nelson Ph.D.Chief Scientific Officer-
Mr. Rafael TejadaVice President of Investor Relations-
Mr. Thomas Bailey Shropshire Jr.Senior VP and General Counsel-
Ms. Sandy B. PoundVP & Chief Communications Officer-
Mr. Alan J. MalusSenior Vice President of Strategy & Corporate Development65

Audit जोखिम

2

बोर्ड जोखिम

7

मुआवजा जोखिम

10

शेयरधारक अधिकार जोखिम

1

भाग 2 · कीमत और खरीदने का समय

यह हिस्सा यह नहीं बताता कि कंपनी अच्छी है या नहीं: यह तय करने में मदद करता है कि उसे कब खरीदें, जब फंडामेंटल आपको आश्वस्त कर चुके हों। इसमें: तकनीकी विश्लेषण, संभावना, ऐतिहासिक गिरावट, गामा एक्सपोज़र।

दस्तावेज़

  • वार्षिक रिपोर्ट (10-K)

    कंपनी के कारोबार, वित्तीय नतीजों और जोखिमों का वार्षिक सिंहावलोकन।

    दाखिल तिथि: 2026-02-26

    दस्तावेज़ देखें
  • तिमाही रिपोर्ट (10-Q)

    पिछले तीन महीनों के वित्तीय प्रदर्शन का अपडेट।

    दाखिल तिथि: 2026-07-31

    दस्तावेज़ देखें
  • विशेष रिपोर्ट (8-K)

    किसी बड़ी घटना, जैसे नेतृत्व में बदलाव या बड़ी घोषणा, की सूचना।

    दाखिल तिथि: 2026-07-23

    दस्तावेज़ देखें

via SEC EDGAR

आय का इतिहास

via SEC EDGAR

Latest News

Recent headlines for TMO, sourced from Markets Gazette.

  • 5/25/2026POSITIVE
    If You Invested $1000 In Thermo Fisher Scientific Stock 20 Years Ago, You Would Have This Much Today

    An investment of $1000 in Thermo Fisher Scientific (TMO) stock 20 years ago would have yielded a substantial return, illustrating the company's long-term growth trajectory. While the exact final value is not provided in this snippet, historical performance data suggests significant capital appreciation. This underscores Thermo Fisher's consistent operational success and market leadership in the life sciences and diagnostics sectors. Investors considering TMO should note its history of innovation and strategic acquisitions, which have contributed to its robust financial performance and shareholder value creation over the past two decades.

  • 3/12/2026POSITIVE
    Here's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today

    An investment of $100 in Thermo Fisher Scientific (TMO) 15 years ago would have grown to approximately $1,040 today, representing a substantial 940% return. This performance significantly outpaced the broader market during the same period. The company's consistent growth trajectory, driven by its diversified portfolio in life sciences, diagnostics, and laboratory products, has been a key factor in its stock's appreciation. Investors who held TMO stock have benefited from its strong operational execution and strategic acquisitions, underscoring its resilience and long-term value creation potential.

  • 3/2/2026NEUTRAL
    Here's How Much $100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth Today

    A retrospective analysis highlights the remarkable performance of Thermo Fisher Scientific, revealing how a $100 investment made two decades ago would have generated substantial returns for today's investors. While this study doesn't provide direct future guidance, it underscores the company's ability to create long-term value, driven by its leadership in life sciences, diagnostics, and research. Consistent growth and innovation have allowed Thermo Fisher to solidify its market position, transforming a modest initial capital into a significantly larger sum. For investors, this serves as a reminder of the importance of patience and selecting companies with strong fundamentals and a lasting competitive advantage.

via Markets Gazette

Disclaimer

यह प्लेटफ़ॉर्म केवल शैक्षिक उद्देश्यों के लिए है। यह कोई वित्तीय, निवेश, या ट्रेडिंग सलाह नहीं देता। सभी स्कोर, मूल्यांकन, और संकेत सार्वजनिक रूप से उपलब्ध डेटा के स्वचालित विश्लेषण पर आधारित हैं जो अधूरे या गलत हो सकते हैं। निवेश निर्णय लेने से पहले हमेशा अपना शोध करें और एक योग्य वित्तीय सलाहकार से परामर्श लें।

निर्मित द्वारा CODEPRESS s.r.l.